These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22111692

  • 1. Renal resistive index in 55 dogs with degenerative mitral valve disease.
    Chetboul V, Daste T, Gouni V, Concordet D, Trehiou-Sechi E, Serres F, Pouchelon JL, Germain CA, Layssol-Lamour C, Lefebvre HP.
    J Vet Intern Med; 2012; 26(1):101-8. PubMed ID: 22111692
    [Abstract] [Full Text] [Related]

  • 2. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V.
    J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
    [Abstract] [Full Text] [Related]

  • 3. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K, Elliott J.
    J Vet Intern Med; 2012 Dec; 26(2):302-11. PubMed ID: 22369312
    [Abstract] [Full Text] [Related]

  • 4. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: a pilot study.
    Schmidt MK, Reynolds CA, Estrada AH, Prosek R, Maisenbacher HW, Sleeper MM, Oyama MA.
    J Vet Cardiol; 2009 May; 11 Suppl 1():S81-6. PubMed ID: 19394913
    [Abstract] [Full Text] [Related]

  • 5. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease.
    Chetboul V, Serres F, Tissier R, Lefebvre HP, Sampedrano CC, Gouni V, Poujol L, Hawa G, Pouchelon J-.
    J Vet Intern Med; 2009 May; 23(5):984-94. PubMed ID: 19572913
    [Abstract] [Full Text] [Related]

  • 6. Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method.
    Gouni V, Serres FJ, Pouchelon JL, Tissier R, Lefebvre HP, Nicolle AP, Sampedrano CC, Chetboul V.
    J Am Vet Med Assoc; 2007 Aug 01; 231(3):399-406. PubMed ID: 17669041
    [Abstract] [Full Text] [Related]

  • 7. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease.
    Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J.
    J Small Anim Pract; 2010 Feb 01; 51(2):84-96. PubMed ID: 20070494
    [Abstract] [Full Text] [Related]

  • 8. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Feb 01; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 9. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG, Falk T, Teerlink T, Guðmundsdóttir HH, Sigurðardóttir S, Rasmussen CE, Olsen LH.
    Vet J; 2011 Sep 01; 189(3):349-52. PubMed ID: 20822939
    [Abstract] [Full Text] [Related]

  • 10. The cardiac biomarker NT-proBNP is increased in dogs with azotemia.
    Raffan E, Loureiro J, Dukes-McEwan J, Fonfara S, James R, Swift S, Bexfield N, Herrtage ME, Archer J.
    J Vet Intern Med; 2009 Sep 01; 23(6):1184-9. PubMed ID: 19709357
    [Abstract] [Full Text] [Related]

  • 11. Azotemia and glomerular filtration rate in dogs with chronic valvular disease.
    Nicolle AP, Chetboul V, Allerheiligen T, Pouchelon JL, Gouni V, Tessier-Vetzel D, Sampedrano CC, Lefebvre HP.
    J Vet Intern Med; 2007 Sep 01; 21(5):943-9. PubMed ID: 17939547
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ, Brodbelt DC, Church DB, Boswood A.
    J Vet Intern Med; 2019 Mar 01; 33(2):445-454. PubMed ID: 30565334
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.
    Mattin MJ, Boswood A, Church DB, Brodbelt DC.
    J Vet Intern Med; 2019 Mar 01; 33(2):432-444. PubMed ID: 30357909
    [Abstract] [Full Text] [Related]

  • 14. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rate of left ventricular pressure change by Doppler echocardiography in dogs with chronic mitral valve disease at different stages of congestive heart failure.
    Kim YH, Choi GJ, Park C.
    Vet Radiol Ultrasound; 2018 Nov 09; 59(6):758-766. PubMed ID: 30184293
    [Abstract] [Full Text] [Related]

  • 18. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 09; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 19. Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease.
    Strunz CMC, Marcondes-Santos M, Takada JY, Fragata FS, Mansur AP.
    Arq Bras Cardiol; 2017 Apr 09; 108(4):347-353. PubMed ID: 28380134
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Apr 09; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.